IMV Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a IMVIF research report →
About the company
IMV Inc. is a biopharmaceutical firm focused on immuno-oncology, currently in the clinical development stage. The company leverages its proprietary DPX immune-modulating platform to create a diverse range of treatments aimed at both solid tumors and blood cancers.
- CEO
- Andrew Hall
- IPO
- 2013
- Employees
- 63
- HQ
- Dartmouth, NS, CA
Price Chart
- Market Cap
- $23.42K
- P/E
- -0.18
- P/S
- 0.00
- P/B
- -1.00
- EV/EBITDA
- -0.46
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -495.17%
- ROIC
- -172.47%
- Revenue
- $0 · 0.00%
- Net Income
- $-36,485,694 · -0.60%
- EPS
- $-4.37 · 10.63%
- Op Income
- $-38,671,513
- FCF YoY
- 0.15%
- 52W High
- $0.00
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- 0.30
- Avg Volume
- 80
Get TickerSpark's AI analysis on IMVIF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our IMVIF coverage
Recent articles, reports, and earnings notes.
No research on IMVIF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate IMVIF report →Similar companies
Peers in the same neighborhood.